Statements in this presentation regarding Akebia's strategy, plans, prospects, expectations, beliefs, intentions or goals are forward-looking statements within the meaning of the Private Securities Litigation Reform Act

January 2019 Exhibit 99.1

Statements in this presentation

regarding Akebia's strategy, plans, prospects, expectations, beliefs, intentions or goals are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including but not limited to

statements regarding the expected period of time our cash resources and estimated product revenue will fund operations; the timing, availability and presentation of clinical trial data and results; the commercial potential, growth potential and

market opportunity for our product and, if approved, our product candidates; our strategy, mission and vision; potential for our product candidates to set a new standard of care; the potential benefits of our product candidates; the timing of

enrollment, including full enrollment, of our clinical trials; the target enrollments of our clinical trials; the assessments and evaluations we expect from our clinical programs; the potential to be a partner of choice for innovation in renal; and

exploring co-development potential for vadadustat and Auryxia. The terms "estimate," "expect," "growth," "momentum," "mission" "opportunity," "positioned,"

"potential," "vision" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Each forward-looking statement is subject to

risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including the actual product revenues for Auryxia; the timing of generic entrants for Auryxia, vadadustat or any other

product candidates; the rate of enrollment in clinical studies of vadadustat; the risk that clinical trials may not be successful; the risk that existing preclinical and clinical data may not be predictive of the results of ongoing or later clinical

trials; manufacturing risks; the quality and manner of the data that will result from clinical studies of vadadustat; the actual funding required to develop and commercialize Akebia's product candidates and operate the company, and the actual

expenses associated therewith; efficacy, safety and tolerability of our products and product candidates; the risk that clinical studies need to be discontinued for any reason, including for safety, tolerability, enrollment, manufacturing or economic

reasons; early termination of any of Akebia's collaborations or license agreements, and the parties' ability to satisfy their obligations under such agreements; the timing and content of decisions made by regulatory, judicial or similar

authorities; the timing of any additional studies initiated for vadadustat; the actual time it takes to initiate and complete research and clinical studies; the success of competitors in developing product candidates for diseases for which Akebia is

currently developing its product candidates; the scope, timing, and outcome of any ongoing legal proceedings; changes in the economic and financial conditions of the businesses of Akebia and its partners; and Akebia's ability to obtain, maintain and

enforce patent and other intellectual property protection for Auryxia, vadadustat and its other product candidates. Other risks and uncertainties include those identified under the heading "Risk Factors" in Akebia's Quarterly

Report on Form 10-Q for the quarterly period ended September 30, 2018, filed with the SEC on November 8, 2018, and other filings that Akebia may make with the SEC in the future, and those identified under the heading "Risk Factors" in

the Quarterly Report on Form 10-Q of Keryx Biopharmaceuticals, Inc., Akebia's wholly owned subsidiary, for the quarterly period ended September 30, 2018, filed with the SEC on November 8, 2018. These forward-looking statements (except as

otherwise noted) speak only as of the date of this presentation, and Akebia does not undertake, and specifically disclaims, any obligation to update any forward-looking statements contained in this presentation. Vadadustat is an investigational drug

and has not yet been approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority. Cautionary Note on Forward-Looking Statements

Akebia: Fully integrated biotech

company focused on kidney disease with complementary portfolio and financial strength Product revenue in two FDA-approved indications with substantial growth potential Multiple clinical catalysts over next 18 months for Phase 3 product candidate

with multi-billion-dollar global market opportunity Expect existing cash resources1 and estimated product revenue to fund operations into Q3 2020 Financial strength with $431 million cash position2, product sales and collaboration revenue 1 Includes

prepaid quarterly committed cost share funding from Akebia's collaborators. 2 Cash, cash equivalents and available for sale securities, pro forma, unaudited, as of 9/30/2018.

Akebia's mission is to advance

care for patients with kidney disease SOURCES: 1 United States Renal Data System. 2018 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and

Kidney Diseases, Bethesda, MD, 2018. NOTE: Adjusted values; Adjusted using direct standardization for age, sex and race. Improved health of patients with kidney disease through better disease management and novel therapeutics High unmet needs OUR

VISION Deaths per 1,000 Patient Years by CKD status (adjusted)1

Kidney disease is a major public health

challenge in the US and globally *Quality of Life. SOURCES: 1 Centers for Disease Control and Prevention. Chronic Kidney Disease Surveillance System-United States. http://www.cdc.gov/ckd.; 2 United States Renal Data System. 2018 USRDS

annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2018.; 3 Centers for Disease Control and Prevention; Kidney in

body. Digital Image. The Ron & Joy Paul Kidney Center. https://smhs.gwu.edu/kidneycenter/about-kidney-disease. Cardio-metabolic disorders Genetic diseases of the kidney Auto-immune disorders Aging & other Chronic Kidney Disease Acute Kidney

Injury Dialysis or Transplant US Dept of Health and Human Services and American Society of Nephrology (ASN) public-private partnership to improve the lives of the 850 million people worldwide currently affected by kidney diseases by accelerating

innovation in the prevention, diagnosis and treatment of kidney diseases KIDNEY DISEASE > 40 million1 > 500k2 US PATIENTS MEDICARE SPENDING LOCATION > $79 billion3 > $35 bil.3 Dialysis clinics Nephrology clinics Hospital Increased

mortality, increased hospitalizations, reduced QoL*

Akebia: Fully integrated biotech

company focused on kidney disease with complementary portfolio and financial strength 1 Hypoxia Inducible Factor Prolyl Hydroxylase. 2 Includes prepaid quarterly committed cost share funding from Akebia's collaborators. 3 Cash, cash

equivalents and available for sale securities, pro forma, unaudited, as of 9/30/2018. Commercial operations with renal focus Research, manufacturing and development, including cardiovascular outcomes trials (CVOT) expertise Expect existing cash

resources2 and estimated product revenue to fund operations into Q3 2020 Financial strength with $431 million cash position3, product sales and collaboration revenue Auryxia (ferric citrate) FDA approved in two indications, showing strong

commercial momentum HYPERPHOSPHATEMIA IN DIALYSIS IRON DEFICIENCY ANEMIA IN NON-DIALYSIS Vadadustat, an investigational HIF PH1 inhibitor In global Phase 3 with read-outs expected beginning 2019 ANEMIA DUE TO CKD IN DIALYSIS ANEMIA DUE TO CKD IN

NON-DIALYSIS COMMERCIALIZED DEVELOPMENT PROGRAM

Different market dynamics in dialysis

vs. non-dialysis, with opportunity for adoption in large existing dialysis market and for high growth potential in non-dialysis market 1 Most injectable drugs and biologics and their oral or other form of administration are included, specifically

erythropoiesis-stimulating agents (ESAs), vitamin D, IV iron. CMS Bundle reimbursement of covered drugs1 High treatment rates Large patient population with lower treatment rates for CKD conditions Payer reimbursement Key unmet needs: cardiovascular

(CV) risk, QoL Key unmet needs: CV risk, delay CKD progression, improved convenience, QoL MULTIPLE COMPLICATIONS ASSOCIATED WITH REDUCTION OF RENAL FUNCTION, INCLUDING: CURRENT FOCUS: Hyperphosphatemia (increasing phosphorus levels) Iron Deficiency

Anemia (decreasing iron levels) Anemia due to CKD (decreasing erythropoietin (EPO) production) Other complications include hypercalcemia, hyperkalemia, hyponatremia, hypernatremia, hyperparathyroidism

Complementary portfolio with strong

commercial potential in dialysis and non-dialysis *Subject to the regulatory authorities approval; SOURCES: 1 DRG CKD Dialysis Market Forecast.; 2 Evaluate Pharma ESA WW sales extraction (07/2018).; 3 Subject to the accrual of Major Adverse

Cardiovascular Events (MACE). OPPORTUNITY: ADOPTION POTENTIAL IN LARGE MARKET OPPORTUNITY: HIGH GROWTH POTENTIAL Auryxia FDA approved in two indications HYPERPHOSPHATEMIA IN DIALYSIS IRON DEFICIENCY ANEMIA IN NON-DIALYSIS Vadadustat, Investigational

HIF PH inhibitor Global Phase 3 studies ANEMIA DUE TO CKD IN DIALYSIS* ANEMIA DUE TO CKD IN NON-DIALYSIS* Gain share in $1b1 US phosphate binder market leveraging competitive profile Gain rapid adoption in a multi-billion-dollar global market2 with

potential to set new oral SoC Majority of patients fail other oral iron therapies creating large US opportunity Seize high growth opportunity in under-treated population with potential to set new oral SoC Read-outs expected: In Japan 2019 for

dialysis and non-dialysis, in US/EU Q1 2020 for dialysis and mid-2020 for non-dialysis3 COMMERCIALIZED DEVELOPMENT PROGRAM

2018 Auryxia commercial performance

shows strong momentum driven by hyperphosphatemia use SOURCE: Monthly prescription and market share data as of 11/30/18. 1 Iron deficiency anemia 2 Prior authorization. Total 2018 prescriptions up 91% YTD Nov'18 vs. Nov'17 Market share

growth from 2.2% to 6.4% in 18 months Well positioned to navigate headwinds and harness momentum to drive continued significant growth in 2019 New Guidelines for hyperphosphatemia Competitive profile, and high share of voice CMS coverage - current

decision to exclude IDA1, leading to PA2 + - + Integration following merger close ongoing DaVita Rx specialty pharma discontinuation - Number of prescriptions Market share

Strong momentum for Auryxia in

phosphate binder market Phosphate Binder Market Needs2 Non-calcium Less pill burden Favorable tolerability profile Palatable formulation Change in Phosphate Binder TRx (000s) 2017 to 20181 SOURCES: 1 IQVIA NPA Data; Fresenius Rx, DaVita Rx &

USRC Dispense Data.; 2 Combined information from physician-reported phosphate binder attribute scoring from both Spherix syndicated market research (RealTime Dynamix quarterly reports) and Reason Research ATU tracking studies. *Brand + Generic

Auryxia Velphoro Lanthanum* Calcium Sevelamer*

Major growth opportunity for Auryxia

in the hyperphosphatemia market following treatment guideline update SOURCES: 1 Phosphate Binder Use, by type. DOPPS Practice Monitor. https://www.dopps.org/dpm/DPMSlideBrowser.aspx. Accessed 12.21.2018.; 2 KDIGO 2017 Clinical Practice Guideline

Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD), Kidney International Supplements (2017) 7, 1-59.; 3 Spherix Global Insights Bone and Mineral Metabolism,

quantitative market research survey, Q4 2018, n=195 nephrologists, "Please rate your level of agreement with the following statement: As a result of KDIGO CKD-MBD guideline update, I anticipate decreasing my use of ca-based binders in my

dialysis patients". Calcium-based binders comprise significant portion of market1 "In adult patients with CKD G3a-G5D receiving phosphate-lowering treatment, we suggest restricting dose of calcium-based phosphate binders" -

KDIGO 2017 Practice Guideline Update2 recent guideline limits their use nephrologists anticipate adoption of updated guideline "As a result of KDIGO CKD-MBD guideline update, I anticipate decreasing my use of ca-based binders in

my dialysis patients3" Other Calcium + Sevelamer only Calcium-based only Agree Neutral Disagree

Patient dissatisfaction with

standard of care (SoC) and nephrologist positive perception of Auryxia create two-pronged tailwinds in the hyperphosphatemia market ~20% patients discontinue use of Renvela1 65% cite pill burden 42% cite tolerability issues Nephrologists view

Auryxia's profile favorably compared to other binders "If you yourself (nephrologist) had to take a phosphate binder, which would you choose?"3 Nephrologists anticipate prescribing 35% more Auryxia 6 months from now2 SOURCES: 1

Spherix Global Insights Bone and Mineral Metabolism, quantitative market research survey, Q4 2018, n=195 nephrologists, "Considering your use of Auryxia, Velphoro and Renvela, what percent of all the patients you prescribed these agents for in

the past six months have since discontinued the brand (e.g. have been switched to a different brand or discontinued altogether)?", "To what extent are the following reasons that patients typically discontinue AURYXIA, VELPHORO, RENVELA

1= Rarely/Never, 5= Very Frequently/ Almost Always".; 2 Auryxia ATU Q4 2018, n = 104 nephrologists.; 3 Spherix Global Insights Bone and Mineral Metabolism, quantitative market research survey, Q4 2018, n=195 nephrologists.

Vadadustat is an oral HIF PH

inhibitor designed to stimulate endogenous EPO production, with the potential to increase hemoglobin while avoiding supra-physiological EPO levels High EPO level is associated with increased CV risk SoC with injectable ESAs result in

supra-physiological EPO levels Vadadustat, oral HIF PH inhibitor, avoided supra-physiological EPO levels Kaplan-Meier Survival Curves1 Death, Heart Failure, Stroke, Myocardial Infarction SOURCES: 1 McCullough P.A., et al. Am J Nephrol

2013;37:549-558 (DOI:10.1159/000351175); Permission granted by S. Karger AG, Basel.; 2 Doshi S et al. Journal of Clinical Pharmacology, 2010;50:75S-90S. Original figure redrawn to depict darbepoetin alfa serum concentration (ng/mL/(mcg/kg))

converted to mU/mL. Data from 6 clinical studies conducted with extensive PK sampling in CKD patients following subcutaneous (SC) administration of a single dose or first dose of a monthly dosing regimen ranging from 0.4-0.6mcg/kg, dose normalized

to 0.45 mcg/kg.; 3 Akebia Therapeutics, Inc. Data on File (2010). Data from Phase 1 study in healthy volunteers with vadadustat once daily dosing. Pre-dose EPO concentrations were evaluated on Days 1, 4, 7, 11, 15 and 22. Post-dose data to assess

acute rise in EPO following vadadustat dosing was only completed on Day 1 and Day 7 (8 and 16 hours post-dose). Dashed line represents estimated EPO levels based on post-dose data from Day 1 and Day 7. EPO vs Time with Darbepoetin Alfa (SC) PK-PD

Model in CKD Subjects2 Median EPO Concentration (mIU/mL) EPO vs Time with vadadustat (Oral) Phase 1 Study in Healthy Volunteers3 NOT A HEAD-TO-HEAD COMPARISON Dashed line represents simulated EPO data Median EPO Concentration (mIU/mL) Vadadustat now

in Phase 3 cardiovascular outcomes trials for anemia due to CKD in non-dialysis and dialysis patients. Vadadustat is an investigational HIF PH inhibitor that is not approved by the FDA or any other regulatory authority.

Global Phase 3 program for

vadadustat designed to assess efficacy, safety and cardiovascular outcomes, with additional data to support value proposition Efficacy and adjudicated safety EPs consistent with INNO2VATE (but not powered for MACE) Conversion from ESA, TIW dosing

PRO Additional Non-Primary Endpoints (EPs): Individual MACE components Chronic Heart Failure Thrombotic Events Hospitalizations Hb excursions Time in range (Hb) IV iron use NDA/MAA core package Support value proposition New-Onset Dialysis Vadadustat

vs Darbepoetin Alfa ESA Treated Vadadustat vs Darbepoetin Alfa N 3600 Primary Efficacy Endpoint: Change in hemoglobin (Hb) from baseline Primary Safety Endpoint: Major Adverse Cardiovascular Events (MACE) Open-label, efficacy, safety, PK/PD

in DD1-CKD, control arm epoetin alfa, modified once daily (QD) and Three Times a Week (TIW) dosing, and ESA Hyporesponders, N125 FO2RWARD-2 Open-label, Sponsor-Blind, parallel arm study evaluating efficacy and safety of Modified QD dosing of

vadadustat compared to epoetin alfa, N EXPLO2RE Open-label, Sponsor-Blind, parallel arm study evaluating efficacy and safety of TIW dosing of vadadustat compared to epoetin alfa, N TRILO2GY-2 Modified QD and TIW dosing Includes ESA

Hyporesponders Conversion from epoetin alfa Efficacy and adjudicated safety EPs consistent with INNO2VATE (but not powered for MACE) Conversion from ESA, Modified QD dosing PRO2 Supplemental filing NDA/MAA filings Cardiovascular Outcomes INNO2VATE

Phase 3 Studies 1 Dialysis-dependent 2 Patient-reported outcomes

Concentration into large US dialysis

networks creates major opportunity for vadadustat *Subject also to inclusion in the ESRD bundle. SOURCES: 1 ESA Use, by type. DOPPS Practice Monitor. https://www.dopps.org/dpm/DPMSlideBrowser.aspx. Accessed 12/19/2018.; 2 TDAPA: Transitional drug

add-on payment adjustment, CMS Ruling CMS-1691-F. Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury, End-Stage Renal Disease Quality Incentive

Program, Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Competitive Bidding Program (CBP) and Fee Schedule Amounts, and Technical Amendments to Correct Existing Regulations Related to the CBP for Certain DMEPOS. Unique

market dynamics with treatment adoption driven by protocols Agreement with Vifor (International) Ltd. positions vadadustat for rapid uptake in Fresenius LDO subject to FDA approval* TDAPA 2 creates major additional opportunity for value creation for

Advanced non-dialysis CKD is

characterized by progressive laboratory abnormalities, with opportunity for better disease management SOURCES: 1 Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Juppner H, Wolf M: Fibroblast growth factor-23 mitigates

hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16: 2205-2215, 2005.; 2 Pereira RC, Juppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry K : Patterns of FGF-23, DMP1, and MEPE

expression in patients with chronic kidney disease. Bone 45: 1161-1168, 2009. 3 United States Renal Data System. 2017 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National

Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2018. Phosphorus (P), Vitamin D (1,25D), PTH and FGF 231,2 Hemoglobin before and after dialysis initiation3 >10,000 1000 90 60 30 4 >90 75 60 45 30 15 0 3 6 >12 Dialysis